A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women.

BACKGROUND Inflammatory cytokines, including tumor necrosis factor alpha, IL-6 (interleukin 6), and high-sensitivity C-reactive protein (hsCRP), have been related to both insulin resistance and type 2 diabetes mellitus. However, prospective studies that comprehensively assess their roles in the development of type 2 diabetes are few, especially in minority populations. METHODS Among 82,069 postmenopausal women aged 50 to 79 years without cardiovascular disease or diabetes mellitus who participated in the Women's Health Initiative Observational Study, we prospectively examined the relationships of plasma levels of tumor necrosis factor alpha receptor 2, IL-6, and hsCRP to diabetes risk. During a median follow-up period of 5.9 years, 1584 women who had clinical diabetes were matched by age, ethnicity, clinical center, time of blood draw, and duration of follow-up to 2198 study participants who were free of the disease. RESULTS After adjustment for matching factors and known diabetes risk factors, all 3 markers were significantly associated with increased diabetes risk; the estimated relative risks comparing the highest with the lowest quartiles were 1.47 (95% confidence interval [CI], 1.10-1.97) for tumor necrosis factor alpha receptor 2, 3.08 (95% CI, 2.25-4.23) for IL-6, and 3.46 (95% CI, 2.50-4.80) for hsCRP (P for trend, <.01 for all biomarkers). When mutually adjusted, IL-6 and hsCRP remained significant in each ethnic group. While no statistically significant interactions were observed between ethnicity and these biomarkers on diabetes risk, there were consistent trends for the associations of hsCRP and IL-6 with increased diabetes risk in all ethnic groups. CONCLUSION These prospective data showed that elevated levels of IL-6 and hsCRP were consistently and significantly associated with an increased risk of clinical diabetes in postmenopausal women.

[1]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[2]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[3]  B. Nicklas,et al.  The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  D. Song,et al.  Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. , 2004, Metabolism: clinical and experimental.

[5]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[6]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Hofman,et al.  Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. , 2001, The Journal of clinical endocrinology and metabolism.

[8]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[9]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[10]  W. Rathmann,et al.  Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. , 2002, Diabetologia.

[11]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[12]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[13]  C. Stehouwer,et al.  Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. , 2002, Atherosclerosis.

[14]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[15]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[16]  P. Ridker,et al.  C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). , 2004, The American journal of cardiology.

[17]  J. Pickup Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.

[18]  C. Meisinger,et al.  C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. , 2003, Archives of internal medicine.

[19]  E. Ford Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. , 2002, American journal of epidemiology.

[20]  K. Suzuki,et al.  White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men , 2002, Diabetologia.

[21]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[22]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[23]  S. Coppack,et al.  Adipose tissue as an endocrine and paracrine organ , 1998, International Journal of Obesity.

[24]  L. Kuller,et al.  The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. , 2001, Diabetes.

[25]  Irving Kushner,et al.  C-reactive Protein* , 2004, Journal of Biological Chemistry.

[26]  R. Prentice,et al.  Biostatistical issues and concepts in epidemiologic research. , 1986, Journal of chronic diseases.

[27]  Scott Davis,et al.  Implementation of the Women's Health Initiative study design. , 2003, Annals of epidemiology.

[28]  L. Niskanen,et al.  C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men , 2004, Diabetologia.

[29]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[30]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[31]  M. Hanefeld,et al.  Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. , 2002, Metabolism: clinical and experimental.

[32]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[33]  W. Rathmann,et al.  Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors , 2002, Diabetologia.

[34]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[35]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[36]  N. Sattar,et al.  C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. , 2002, Diabetes.

[37]  Z. Bloomgarden Inflammation, atherosclerosis, and aspects of insulin action. , 2005, Diabetes care.

[38]  S. Bandinelli,et al.  Diverse Effect of Inflammatory Markers on Insulin Resistance and Insulin‐Resistance Syndrome in the Elderly , 2004, Journal of the American Geriatrics Society.

[39]  M. Visser,et al.  Prospective relation of C-reactive protein with type 2 diabetes: response to Han et al. , 2003, Diabetes care.

[40]  N. Sattar,et al.  Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. , 2002, Diabetes care.

[41]  B. Wajchenberg Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[42]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[43]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[44]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[45]  S. Coppack,et al.  Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome , 1997, Diabetes.

[46]  J. Flier,et al.  Adipose Tissue as an Endocrine Organ , 2014 .

[47]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.